The role of CD44 in glioblastoma multiforme

Journal of Clinical Neuroscience

Volumn 34, Issue , 2016, Pages 1-5

  Mooney, Kelly L ^a   Choy, Winward ^a   Sidhu, Sabrin ^a   Pelargos, Panayiotis ^a   Bui, Timothy T ^a   Voth, Brittany ^a   Barnette, Natalie ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD44 protein; CD44v6 antigen; Glioblastoma multiforme

Indexed keywords

ANTINEOPLASTIC AGENT; BIVATUZUMAB MERTANSINE; DOXORUBICIN; HERMES ANTIGEN; LIVER ENZYME; NANOPARTICLE; POLYGLACTIN; RO 5429083; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; CANCER RADIOTHERAPY; CARCINOGENESIS; CD44 GENE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTATIC BREAST CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISEASE; TUMOR INVASION; VOMITING; BRAIN NEOPLASMS; METABOLISM;

ANTIGENS, CD44; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS;

EID: 84994430535     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2016.05.012     Document Type: Review

References (71)

1. [1] Misra, S., Hascall, V.C., Markwald, R.R., et al. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol, 6, 2015, 201.
2. [2] Naor, D., Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer. Front Immunol, 7, 2016, 39.
3. [3] Naor, D., Nedvetzki, S., Golan, I., et al. CD44 in cancer. Crit Rev Clin Lab Sci 39 (2002), 527–579.
4. [4] Naor, D., Wallach-Dayan, S.B., Zahalka, M.A., et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18 (2008), 260–267.
5. [5] Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 (2003), 3983–3988.
6. [6] Choi, S.H., Takahashi, K., Eto, H., et al. CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer 85 (2000), 523–526.
7. [7] Dalerba, P., Dylla, S.J., Park, I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104 (2007), 10158–10163.
8. [8] Gunthert, U., Hofmann, M., Rudy, W., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65 (1991), 13–24.
9. [9] Hebbard, L., Steffen, A., Zawadzki, V., et al. CD44 expression and regulation during mammary gland development and function. J Cell Sci 113 (2000), 2619–2630.
10. [10] Ishimoto, T., Oshima, H., Oshima, M., et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 101 (2010), 673–678.
11. [11] Jijiwa, M., Demir, H., Gupta, S., et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One, 6, 2011, e24217.
12. [12] Ochiai, S., Nakanishi, Y., Mizuno, K., et al. Expression of CD44 standard and CD44 variant 6 in human lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 35 (1997), 1179–1185.
13. [13] Yan, Y., Zuo, X., Wei, D., Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med 4 (2015), 1033–1043.
14. [14] Tsukita, S., Oishi, K., Sato, N., et al. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126 (1994), 391–401.
15. [15] Okamoto, I., Kawano, Y., Murakami, D., et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155 (2001), 755–762.
16. [16] Dzwonek, J., Wilczynski, G.M., CD44: molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci, 9, 2015, 175.
17. [17] Jones, L.L., Liu, Z., Shen, J., et al. Regulation of the cell adhesion molecule CD44 after nerve transection and direct trauma to the mouse brain. J Comp Neurol 426 (2000), 468–492.
18. [18] Shin, T., Ahn, M., Kim, H., et al. Temporal expression of osteopontin and CD44 in rat brains with experimental cryolesions. Brain Res 1041 (2005), 95–101.
19. [19] Wang, X., Xu, L., Wang, H., et al. CD44 deficiency in mice protects brain from cerebral ischemia injury. J Neurochem 83 (2002), 1172–1179.
20. [20] Huse, J.T., Holland, E.C., Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10 (2010), 319–331.
21. [21] Maher, E.A., Furnari, F.B., Bachoo, R.M., et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 15 (2001), 1311–1333.
22. [22] Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18 (2010), 655–668.
23. [23] Breyer, R., Hussein, S., Radu, D.L., et al. Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg 92 (2000), 140–149.
24. [24] Kaaijk, P., Troost, D., Morsink, F., et al. Expression of CD44 splice variants in human primary brain tumors. J Neurooncol 26 (1995), 185–190.
25. [25] Kuppner, M.C., Van Meir, E., Gauthier, T., et al. Differential expression of the CD44 molecule in human brain tumours. Int J Cancer 50 (1992), 572–577.
26. [26] Nagasaka, S., Tanabe, K.K., Bruner, J.M., et al. Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J Neurosurg 82 (1995), 858–863.
27. [27] Resnick, D.K., Resnick, N.M., Welch, W.C., et al. Differential expressions of CD44 variants in tumors affecting the central nervous system. Mol Diagn 4 (1999), 219–232.
28. [28] Xu, Y., Stamenkovic, I., Yu, Q., CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70 (2010), 2455–2464.
29. [29] Ranuncolo, S.M., Ladeda, V., Specterman, S., et al. CD44 expression in human gliomas. J Surg Oncol 79 (2002), 30–35 [discussion 35–6].
30. [30] Wei, K.C., Huang, C.Y., Chen, P.Y., et al. Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30 (2010), 253–259.
31. [31] Phillips, H.S., Kharbanda, S., Chen, R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006), 157–173.
32. [32] Verhaak, R.G., Hoadley, K.A., Purdom, E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
33. [33] Vaillant, B.D., Bhat, K., Sulman, E.P., et al. CD44 as a prognostic and predictive marker for GBM. J Clin Oncol, 29, 2011, 2049.
34. [34] Pietras, A., Katz, A.M., Ekstrom, E.J., et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14 (2014), 357–369.
35. [35] Yoshida, T., Matsuda, Y., Naito, Z., et al. CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int 62 (2012), 463–470.
36. [36] Mao, P., Joshi, K., Li, J., et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 110 (2013), 8644–8649.
37. [37] Merzak, A., Koocheckpour, S., Pilkington, G.J., CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 54 (1994), 3988–3992.
38. [38] Monaghan, M., Mulligan, K.A., Gillespie, H., et al. Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro. J Pathol 192 (2000), 519–525.
39. [39] Asher, R., Bignami, A., Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp Cell Res 203 (1992), 80–90.
40. [40] Radotra, B., McCormick, D., Crockard, A., CD44 plays a role in adhesive interactions between glioma cells and extracellular matrix components. Neuropathol Appl Neurobiol 20 (1994), 399–405.
41. [41] Radotra, B., McCormick, D., Glioma invasion in vitro is mediated by CD44-hyaluronan interactions. J Pathol 181 (1997), 434–438.
42. [42] Feng, C., Zhang, Y., Yin, J., et al. Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro Oncol 16 (2014), 1078–1085.
43. [43] Penar, P.L., Khoshyomn, S., Bhushan, A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 40 (1997), 141–151.
44. [44] Sauter, G., Maeda, T., Waldman, F.M., et al. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 148 (1996), 1047–1053.
45. [45] Zhang, D., Jacobberger, J.W., TGF-beta 1 perturbation of the fibroblast cell cycle during exponential growth: switching between negative and positive regulation. Cell Prolif 29 (1996), 289–307.
46. [46] Murakami, D., Okamoto, I., Nagano, O., et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22 (2003), 1511–1516.
47. [47] Chen, L., Smith, L., Johnson, M.R., et al. Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells. J Biol Chem 275 (2000), 32227–32233.
48. [48] Feng, C., Zuo, Z., Regulatory factor X1-induced down-regulation of transforming growth factor beta2 transcription in human neuroblastoma cells. J Biol Chem 287 (2012), 22730–22739.
49. [49] Bai, Y., Liu, Y.J., Wang, H., et al. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26 (2007), 836–850.
50. [50] Lau, Y.K., Murray, L.B., Houshmandi, S.S., et al. Merlin is a potent inhibitor of glioma growth. Cancer Res 68 (2008), 5733–5742.
51. [51] Fu, J., Yang, Q.Y., Sai, K., et al. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro Oncol 15 (2013), 1353–1365.
52. [52] Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., et al. Cancer stem cells in glioblastoma. Genes Dev 29 (2015), 1203–1217.
53. [53] Singh, S.K., Clarke, I.D., Terasaki, M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003), 5821–5828.
54. [54] Lottaz, C., Beier, D., Meyer, K., et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70 (2010), 2030–2040.
55. [55] Brown, D.V., Mantamadiotis, T., Insights into the next generation of cancer stem cell research. Front Biosci (Landmark Ed) 19 (2014), 1015–1027.
56. [56] Zoller, M., CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells. Front Immunol, 6, 2015, 235.
57. [57] Goodell, M.A., Brose, K., Paradis, G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183 (1996), 1797–1806.
58. [58] Bhat, K.P., Balasubramaniyan, V., Vaillant, B., et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24 (2013), 331–346.
59. [59] Ghosh, S.C., Neslihan Alpay, S., Klostergaard, J., CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Target 16 (2012), 635–650.
60. [60] Misra, S., Heldin, P., Hascall, V.C., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278 (2011), 1429–1443.
61. [61] Okada, H., Yoshida, J., Sokabe, M., et al. Suppression of CD44 expression decreases migration and invasion of human glioma cells. Int J Cancer 66 (1996), 255–260.
62. [62] Wiranowska, M., Ladd, S., Moscinski, L.C., et al. Modulation of hyaluronan production by CD44 positive glioma cells. Int J Cancer 127 (2010), 532–542.
63. [63] Tijink, B.M., Buter, J., de Bree, R., et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12 (2006), 6064–6072.
64. [64] Rupp, U., Schoendorf-Holland, E., Eichbaum, M., et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 18 (2007), 477–485.
65. [65] Park, H.K., Lee, S.J., Oh, J.S., et al. Smart nanoparticles based on hyaluronic acid for redox-responsive and CD44 receptor-mediated targeting of tumor. Nanoscale Res Lett, 10, 2015, 981.
66. [66] Platt, V.M., Szoka, F.C. Jr., Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5 (2008), 474–486.
67. [67] Song, S., Qi, H., Xu, J., et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res 31 (2014), 2988–3005.
68. [68] Dubrow, R., Darefsky, A.S., Jacobs, D.I., et al. Time trends in glioblastoma multiforme survival: the role of temozolomide. Neuro Oncol 15 (2013), 1750–1761.
69. [69] Hegi, M.E., Diserens, A.C., Gorlia, T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005), 997–1003.
70. [70] Johannessen, T.C., Bjerkvig, R., Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12 (2012), 635–642.
71. [71] Veliz, I., Loo, Y., Castillo, O., et al. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?. Ann Transl Med, 3, 2015, 7.